A Phase 3 interventional study of Eravacycline and Levofloxacin in cUTI, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 99 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.
Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy and safety of eravacycline compared with levofloxacin in participants with complicated urinary tract infections (cUTI).
This study began with a 3-arm Lead-in portion to determine the oral (PO) dosing (200 or 250 milligrams [mg]) of eravacycline to be used with intravenously (IV) administered eravacycline for the Pivotal portion (2 arms). A PO dose of 200 mg was selected based on the unblinded Lead-in analysis.
Tetraphase Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), OR b. cUTI with at least 1 of the following conditions associated with a risk for developing cUTI: i. Indwelling urinary catheter ii. Urinary retention (approximately 100 milliliters of residual urine after voiding) iii. Neurogenic bladder iv. Partial obstructive uropathy (such as, nephrolithiasis, bladder stones, and ureteral strictures) v. Azotemia of renal origin (not congestive heart failure or volume related) such that the serum blood urea nitrogen (BUN) is elevated (>20 mg/deciliters) AND the serum BUN: creatinine ratio is \<15 vi. Surgically modified or abnormal urinary tract anatomy (such as, bladder diverticula, redundant urine collection system) EXCEPT surgery within the last month
Exclusion Criteria:
Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.
Drug: Eravacycline
Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.
Drug: Levofloxacin
Also known as: TP-434
Also known as: Levaquin
Participants In The Microbiological Intent-To-Treat (Micro-ITT) Population With A Responder Outcome At The Post-Treatment (PT) Visit
This was the primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to levofloxacin in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
Time frame: PT Visit
Participants In The Microbiological Modified ITT (Micro-MITT) Population With A Microbiological Response
This outcome measure (FDA and the European Medicines Agency \[EMA\]) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the micro-MITT population. Responses were success, failure, or indeterminate/missing. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond end of therapy (EOT) to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available.
Time frame: PT Visit
Participants In The Microbiologically Evaluable (ME) Population With A Microbiological Response
This outcome measure (FDA and EMA) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the ME population. Responses were either success or failure. Indeterminate/missing responses were not included. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond EOT to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available. Populations: ME, all micro-ITT and clinically-evaluable (CE) participants with a suitable urine specimen and an interpretable urine culture; micro-ITT, all participants with ≥1 baseline bacterial pathogen from a urine or blood culture that caused a UTI against which eravacycline had expected antibacterial activity; ITT, all randomized participants, regardless of receiving study drug or not.
Time frame: PT Visit
Participants with a diagnosis of complicated urinary tract infection (cUTI), including participants with acute pyelonephritis, were recruited into this study.
| Milestone | Eravacycline | Levofloxacin |
|---|---|---|
| Started | 455 | 453 |
| Received at least 1 dose of study drug | 454 | 451 |
| Completed | 432 | 439 |
| Not completed | 23 | 14 |
| Withdrew: Lost to follow-up | 12 | 6 |
| Withdrew: Withdrawal by subject | 8 | 4 |
| Withdrew: Adverse event, non-fatal | 2 | 1 |
| Withdrew: Participant noncompliance | 1 | 1 |
| Withdrew: Did not meet inclusion criteria | 0 | 1 |
| Withdrew: Previously scheduled procedure | 0 | 1 |
This was the primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to levofloxacin in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.
| Participants | Eravacycline | Levofloxacin |
|---|---|---|
| Responder | 180 | 202 |
| Non-responder | 100 | 91 |
| Indeterminate | 18 | 9 |
This outcome measure (FDA and the European Medicines Agency \[EMA\]) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the micro-MITT population. Responses were success, failure, or indeterminate/missing. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond end of therapy (EOT) to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available.
| Participants | Eravacycline | Levofloxacin |
|---|---|---|
| Success | 194 | 213 |
| Failure | 85 | 78 |
| Indeterminate/missing | 18 | 11 |
This outcome measure (FDA and EMA) compared the microbiological responses of eravacycline to levofloxacin for both treatment groups in the ME population. Responses were either success or failure. Indeterminate/missing responses were not included. Success was considered a reduction of the baseline pathogen(s) to \<10\^4 CFU/mL. Failure required blood cultures at or beyond EOT to be positive for baseline pathogen(s), or urine culture to grow ≥10\^4 CFU/mL of the baseline pathogen(s). Indeterminate/missing indicated no interpretable culture data available. Populations: ME, all micro-ITT and clinically-evaluable (CE) participants with a suitable urine specimen and an interpretable urine culture; micro-ITT, all participants with ≥1 baseline bacterial pathogen from a urine or blood culture that caused a UTI against which eravacycline had expected antibacterial activity; ITT, all randomized participants, regardless of receiving study drug or not.
| Participants | Eravacycline | Levofloxacin |
|---|---|---|
| Success | 180 | 203 |
| Failure | 75 | 73 |
Collected over The time frame for adverse event reporting was from the first dose of study drug through 30 days after the last dose of study drug or the late post-treatment visit (whichever was later).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eravacycline | 1/455 (0.2%) | 7/455 (1.5%) | 129/455 (28.4%) |
| Levofloxacin | 0/450 (0%) | 6/450 (1.3%) | 26/450 (5.8%) |
| Event | Eravacycline | Levofloxacin |
|---|---|---|
| Pericardial effusionCardiac disorders | 0/455 | 1/450 |
| DiarrhoeaGastrointestinal disorders | 0/455 | 1/450 |
| OrchitisInfections and infestations | 0/455 | 1/450 |
| PneumoniaInfections and infestations | 0/455 | 1/450 |
| Psoas abscessInfections and infestations | 0/455 | 1/450 |
| Urinary retentionRenal and urinary disorders | 0/455 | 1/450 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/455 | 0/450 |
| Pancreatitis acuteGastrointestinal disorders | 1/455 | 0/450 |
| Suicide attemptPsychiatric disorders | 1/455 | 0/450 |
| Renal colicRenal and urinary disorders | 1/455 | 0/450 |
| Event | Eravacycline | Levofloxacin |
|---|---|---|
| NauseaGastrointestinal disorders | 82/455 | 14/450 |
| VomitingGastrointestinal disorders | 33/455 | 6/450 |
| HeadacheNervous system disorders | 14/455 | 6/450 |
The intent-to-treat (ITT) population consisted of all randomized participants regardless of whether or not the participant received study drug.
| Age, Categorical(Participants) | Eravacycline | Levofloxacin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 291 | 301 | 592 |
| >=65 years | 164 | 152 | 316 |
| Age, Continuous(years) | Eravacycline | Levofloxacin | Total |
|---|---|---|---|
| Mean | 53.7 ± 18.82 | 51.7 ± 19.81 | 52.7 ± 19.3 |
| Sex: Female, Male(Participants) | Eravacycline | Levofloxacin | Total |
|---|---|---|---|
| Female | 291 | 302 | 593 |
| Male | 164 | 151 | 315 |
Ran from Oct 2014 to primary completion in Jun 2015, 7 months.
Results were first posted in Dec 2018, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eravacycline
Tetraphase Pharmaceuticals, Inc.